Our work here is the first to connect the upregulation and internalization of PTGFRN in various cancer cells with the ability to target PTGFRN via monoclonal antibody to inhibit in vitro proliferation and in vivo tumor growth, thus paving the way for the development of PTGFRN antibody-drug conjugate for these cancer types. This evidence concerns the gene PTGFRN and neoplasm.